Cargando…

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

PURPOSE: Chemoradiation therapy (CRT) for patients with locally advanced pancreatic cancer (LAPC) provides survival benefits but may result in considerable toxicity. Health-related quality of life (HRQL) measurements during CRT have not been widely reported. This paper reports HRQL data from the Sel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurt, Christopher N., Mukherjee, Somnath, Bridgewater, John, Falk, Stephen, Crosby, Tom, McDonald, Alec, Joseph, George, Staffurth, John, Abrams, Ross A., Blazeby, Jane M., Bridges, Sarah, Dutton, Peter, Griffiths, Gareth, Maughan, Tim, Johnson, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Inc 2015
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627359/ https://www.ncbi.nlm.nih.gov/pubmed/26530749 http://dx.doi.org/10.1016/j.ijrobp.2015.08.026

Ejemplares similares

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
por: Mukherjee, Somnath, et al.
Publicado: (2013)

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer
por: Hurt, C N, et al.
Publicado: (2017)

Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial
por: Fokas, Emmanouil, et al.
Publicado: (2016)

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer
por: Crosby, T, et al.
Publicado: (2017)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
por: Strauss, Victoria Y., et al.
Publicado: (2019)

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
por: Hurt, Christopher N, et al.
Publicado: (2011)

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer
por: Rees, J, et al.
Publicado: (2015)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma
por: Mukherjee, Somnath, et al.
Publicado: (2015)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
por: Mukherjee, Somnath, et al.
Publicado: (2017)

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy
por: Cox, Samantha, et al.
Publicado: (2017)

SCALOP: sequence-based antibody canonical loop structure annotation
por: Wong, Wing Ki, et al.
Publicado: (2019)

The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial
por: Carrington, Rhys, et al.
Publicado: (2016)

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial
por: Mukherjee, Somnath, et al.
Publicado: (2021)

Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial
por: Adamson, Douglas, et al.
Publicado: (2014)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial
por: Adamson, Douglas, et al.
Publicado: (2021)

Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
por: Warren, Samantha, et al.
Publicado: (2017)

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
por: Mukherjee, Somnath, et al.
Publicado: (2023)

Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer()
por: Warren, Samantha, et al.
Publicado: (2014)

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers
por: Schunke, Kathryn J., et al.
Publicado: (2017)

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
por: Wilson, James M., et al.
Publicado: (2016)

Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas
por: Cox, Samantha J., et al.
Publicado: (2017)

Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy
por: Wills, Lucy, et al.
Publicado: (2017)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation
por: Carrington, Rhys, et al.
Publicado: (2015)

Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SCOPE1
por: Cox, S, et al.
Publicado: (2016)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer
por: Vieira, Heidi M., et al.
Publicado: (2023)

Postoperative chemoradiation for resected gastric cancer - is the Macdonald Regimen Tolerable? a retrospective multi-institutional study
por: Kundel, Yulia, et al.
Publicado: (2011)

NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch
por: O’Cathail, Séan M., et al.
Publicado: (2021)

Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation
por: Russi, Elvio G., et al.
Publicado: (2014)

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
por: Gollins, Simon, et al.
Publicado: (2018)

The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
por: Wang, Zhi-Qiang, et al.
Publicado: (2022)

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study
por: Grenader, Tal, et al.
Publicado: (2016)

Driving developments in UK oesophageal radiotherapy through the SCOPE trials
por: Gwynne, S., et al.
Publicado: (2019)

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation
por: Leong, T, et al.
Publicado: (2003)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation
por: Dricken, Julie, et al.
Publicado: (2020)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

Concurrent Chemoradiation for Vaginal Cancer
por: Miyamoto, David T., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dieucc7sp43f415ii0s2j60btr